This Article Full Text (PDF) All Versions of this Article: 1352458507077621v1 13/8/975    most recent References Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in Web of Science Similar articles in PubMed Alert me to new issues of the journal Add to Saved Citations Download to citation manager Request Permissions Request Reprints Add to My Marked Citations Citing Articles Citing Articles via HighWire Citing Articles via Web of Science (8) Citing Articles via Google Scholar Citing Articles via Scopus Google Scholar Articles by Cocco, E. Articles by Marrosu, M. Search for Related Content PubMed PubMed Citation Articles by Cocco, E. Articles by Marrosu, M. Social Bookmarking                         What's this?

Mitoxantrone treatment in patients with early relapsing-remitting multiple sclerosis

Centro Sclerosi Multipla, Dipartimento di. Scienze Cardiovascolari e Neurologiche, University of Cagliari, Italy

P. Marchi

Centro Sclerosi Multipla, Dipartimento di. Scienze Cardiovascolari e Neurologiche, University of Cagliari, Italy

C. Sardu

Department of Public Health, University of Cagliari, Italy

P. Russo

Department of Critical Area, University of Florence, Italy

A. Paolillo

Department of Critical Area, University of Florence, Italy, Department of Neurological Sciences, University of Rome "La Sapienza", Italy

MG Mascia

Centro Sclerosi Multipla, Dipartimento di. Scienze Cardiovascolari e Neurologiche, University of Cagliari, Italy

M. Solla

Centro Sclerosi Multipla, Dipartimento di. Scienze Cardiovascolari e Neurologiche, University of Cagliari, Italy

J. Frau

Centro Sclerosi Multipla, Dipartimento di. Scienze Cardiovascolari e Neurologiche, University of Cagliari, Italy

L. Lorefice

Centro Sclerosi Multipla, Dipartimento di. Scienze Cardiovascolari e Neurologiche, University of Cagliari, Italy

S. Massole

Centro Sclerosi Multipla, Dipartimento di. Scienze Cardiovascolari e Neurologiche, University of Cagliari, Italy

G. Floris

Centro Sclerosi Multipla, Dipartimento di. Scienze Cardiovascolari e Neurologiche, University of Cagliari, Italy

MG Marrosu

Centro Sclerosi Multipla, Dipartimento di. Scienze Cardiovascolari e Neurologiche, University of Cagliari, Italy

We investigated the clinical and MRI effects of mitoxantrone (MITOX) administered to 45 patients during the first five years of highly active relapsing-remitting multiple sclerosis. Differences occurring between the end of treatment and follow-up (clinical mean: 3.6 years; brain MR: 1.8 years) with respect to baseline variables (EDSS, annualized relapse rate, active T2 lesions, new T1 lesions and number of Gd-enhancing lesions) were analysed using parametric and non-parametric tests. One patient developed leukemia four months after the end of the treatment; no other serious adverse events occurred during treatment and the follow-up period. A clinically relevant reduction in the annualized relapse rate ( P < 0.0001 at end of treatment and P < 0.0001 at follow-up) and improvement in the EDSS (P < 0.0001 at end of treatment and P = 0.0005 at follow-up) was found. At the end of treatment, 53% of patients experienced no increase in active T2 lesions, while 73% showed no increase in the number of new T1 lesions. At follow-up, 41 out of 45 (91%) patients showed a stable MRI pattern and were active-scan free. Despite potential serious adverse events, MITOX may be considered an option in selected patients with very active early MS. Multiple Sclerosis 2007; 13: 975—980. http://msj.sagepub.com

Key Words: brain MRI • disability • early stage • mitoxantrone • multiple sclerosis

This version was published on September 1, 2007

Multiple Sclerosis, Vol. 13, No. 8, 975-980 (2007)
DOI: 10.1177/1352458507077621


CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				R Ellis and M Boggild Therapy-related acute leukaemia with Mitoxantrone: what is the risk and can we minimise it? Multiple Sclerosis, April 1, 2009; 15(4): 505 - 508. [Abstract] [PDF]

				P Coyle, B Arnason, B Hurwitz, and F Lublin Optimizing Outcomes in Multiple Sclerosis - A Consensus Initiative Multiple Sclerosis, February 1, 2009; 15(2_suppl): S5 - S35. [Abstract] [PDF]

				E Cocco, C Sardu, P Gallo, R Capra, M. Amato, M Trojano, A Uccelli, M. Marrosu, and the FEMIMS group* Frequency and risk factors of mitoxantrone-induced amenorrhea in multiple sclerosis: the FEMIMS study Multiple Sclerosis, November 1, 2008; 14(9): 1225 - 1233. [Abstract] [PDF]

				F. Ubiali, S. Nava, V. Nessi, R. Longhi, G. Pezzoni, R. Capobianco, R. Mantegazza, C. Antozzi, and F. Baggi Pixantrone (BBR2778) Reduces the Severity of Experimental Autoimmune Myasthenia Gravis in Lewis Rats J. Immunol., February 15, 2008; 180(4): 2696 - 2703. [Abstract] [Full Text] [PDF]